PubMed HealthSearch

PubMed · 2906173

[Nitrate tolerance].

Abstract

Nitrate tolerance is defined as an attenuation or even loss of hemodynamic and anti-ischemic effects during continuous nitrate medication. The blunted response may be due to the development of pseudotolerance and true pharmacologic tolerance. Pseudotolerance is the result of volume and salt retention, as well as the stimulation of counter-regulatory mechanisms which may alter the baseline hemodynamics of a patient during nitrate therapy. Far less important are changes in nitrate pharmacokinetics. True pharmacological tolerance may also be of practical importance. Diminished uptake of nitrates into the vascular smooth muscle cell, a decrease in intracellular SH groups, inhibition of the guanylate-cyclase, and stimulation of a specific phosphodiesterase may result in a decrease of cyclic GMP formation and hence to a decrease in nitrate induced vasodilatation. Tolerance development may be prevented by intermittent nitrate administration providing intervals with low plasma and tissue nitrate levels. In consequence, nitrates should be used predominantly for treatment of ischemic episodes, but 24-hour anti-ischemic action for the prevention of ischemia can be better achieved by treatment with a beta-blocker and/or a calcium antagonist. Nitrates should be added in times of maximum susceptibility to ischemia, while allowing nitrate levels to fall at other times.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

O Bertel. 1988-12-17. [Nitrate tolerance].. https://pubmed.ncbi.nlm.nih.gov/2906173/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Cardiac allograft arteriopathy: an ischemic burden of a different sort.

As heart transplant recipients live longer, an accelerated and distinct form of coronary artery disease develops that adversely affects survival. Indeed, cardiac allograft arteriopathy may be detected in as many as 90% of heart transplant recipients after 5 years. The precise incidence is not easily determined because the disease can be difficult to recognize when noninvasive tests are used; even angiography has substantive limitations. The distinct characteristics of this type of coronary artery disease result in a different form of chronic ischemic syndrome. The angiographic hallmark of allograft arteriopathy is an extensive, diffuse, obliterative process that primarily involves distal, small, subendocardial arteries. Endothelial injury seems to trigger the disease process. The arteriopathy is likely immunologically mediated and promoted or exacerbated by traditional atherosclerotic disease risk factors. Viral infection may be involved as well. To gain a better understanding of allograft arteriopathy, it is worthwhile to review its incidence, pathophysiology, prognosis, prevention, and treatment.

Coronary Disease